Can I read Radiation dose response in patients with favorable localized prostate cancer (Stage T1–T2, biopsy Gleason ≤ 6, and pretreatment prostate-specific antigen ≤ 10) on EtoBox?

Radiation dose response in patients with favorable localized prostate cancer (Stage T1–T2, biopsy Gleason ≤ 6, and pretreatment prostate-specific antigen ≤ 10) by Patrick A Kupelian; Jeffrey C Buchsbaum; Chandana A Reddy; Eric A Klein is a Medicine article available to read on EtoBox.

What is Radiation dose response in patients with favorable localized prostate cancer (Stage T1–T2, biopsy Gleason ≤ 6, and pretreatment prostate-specific antigen ≤ 10) about?

Purpose: To study the radiation dose response as determined by biochemical relapse-free survival in patients with favorable localized prostate cancers, i.e., Stage T1-T2, biopsy Gleason score (bGS) < 6, and pretreatment prostate-specific antigen (iPSA) < 10 ng/mL. Methods and Materials: A total of 292 patients with favorable localized prostate cancer were treated with radiotherapy alone between 1986 and 1999. The median age was 69 years. Sixteen percent of cases (n ‫؍‬ 46) were African-American. The distribution by clinical T stage was as follows: T1/T2A, 243 (83%); and T2B/T2C, 49 (17%). The distribution by iPSA was as follows: 4 ng/mL, 243 (83%). The mean iPSA level was 6.2 (median, 6.4). The distribution by bGS was as follows: < 5 in 89 cases (30%) and 6 in 203 cases (70%). The median radiation dose was 70.0 Gy (range, 63.0 -78.0 Gy). Doses of < 70.0 Gy were delivered in 175 cases, 70.2-72.0 Gy in 24 cases, 74 Gy in 30 cases, and 78 Gy in 63 cases. For patients receiving 72 Gy. A conformal technique was used in 129 (44%) of cases. The median follow-up was 43 months (range, 3-153). Results: For the entire cohort, the projected 5-and 8-year biochemical relapse-free survival (b

Who reads Radiation dose response in patients with favorable localized prostate cancer (Stage T1–T2, biopsy Gleason ≤ 6, and pretreatment prostate-specific antigen ≤ 10)?

Author

Patrick A Kupelian; Jeffrey C Buchsbaum; Chandana A Reddy; Eric A Klein

Publisher

Elsevier Science; Elsevier ; Elsevier BV (ISSN 0360-3016)

Published

2001

Language

EN

Field

Medicine (Health Sciences)